Jade Biosciences, Inc. (JBIO) Key Metrics
JBIO valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $856.7M
- Enterprise value
- $473.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 2.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
JBIO key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsJBIO returns How much profit the business earns on the capital it uses.
JBIO financial health Debt, liquidity and how easily interest is covered.
JBIO efficiency & capital use Working capital cycle and where the cash goes.
JBIO valuation history
JBIO returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
JBIO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
JBIO price vs earnings per share
JBIO key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $483.9M | — | — | — | — | — |
| Enterprise value | $148.5M | — | — | — | — | — |
| Price / book | 1.5 | — | — | — | — | — |
| Earnings yield | −26.3% | — | — | — | — | — |
| Free cash flow yield | −19.6% | — | — | — | — | — |
| Share price at fiscal year-end | $15.43 | $0.00 | $0.02 | $0.02 | $0.01 | — |
| Per share | ||||||
| Revenue per share | $0.00 | — | — | — | — | — |
| Earnings per share | −$4.06 | — | — | — | — | — |
| Operating cash flow per share | −$3.02 | — | — | — | — | — |
| Free cash flow per share | −$3.03 | — | — | — | — | — |
| Cash per share | $10.72 | — | — | — | — | — |
| Book value per share | $10.60 | — | — | — | — | — |
| Tangible book value per share | $10.60 | — | — | — | — | — |
| Capex per share | $0.01 | — | — | — | — | — |
| Debt per share | $0.02 | — | — | — | — | — |
| Shares outstanding | 31.4M | — | — | — | — | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −62.3% | −74.9% | −63.9% | −34.4% | −26.2% | −326.8% |
| Return on invested capital (ROIC) | — | — | — | — | −912.8% | — |
| Return on assets (ROA) | −59.2% | −67.0% | −57.5% | −33.2% | −25.5% | −203.8% |
| Return on tangible assets | −36.4% | −86.7% | −59.3% | −38.1% | −13.1% | −203.8% |
| Financial health | ||||||
| Total debt | $724,000 | $417,000 | $675,000 | $1.1M | $574,000 | — |
| Cash & short-term investments | $336.2M | $78.6M | $122.4M | $129.2M | $167.4M | $4.6M |
| Net debt | −$335.4M | −$78.2M | −$121.8M | −$128.1M | −$166.8M | −$4.6M |
| Debt / equity | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | — |
| Debt / assets | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | — |
| Current ratio | 20.33 | 20.93 | 7.04 | 16.90 | 68.37 | 2.64 |
| Quick ratio | 20.33 | 20.93 | 7.04 | 16.90 | 68.37 | 2.64 |
| Interest coverage | — | — | — | — | — | -118.5 |
| Working capital | $319.6M | $76.3M | $106.6M | $123.7M | $171.8M | $2.9M |
| Invested capital | −$2.9M | −$1.8M | −$12.3M | −$1.4M | $5.6M | −$1.6M |
| Tangible asset value | $332.5M | $76.4M | $109.5M | $126.7M | $172.4M | $2.9M |
| Net current asset value | $318.9M | $76.2M | $106.3M | $122.9M | $171.4M | $2.9M |
| Graham net-net per share | $10.17 | — | — | — | — | — |
| Capital allocation | ||||||
| Capex / depreciation | 7.54 | 0.00 | 1.48 | 2.87 | 12.07 | 0.00 |
| Efficiency | ||||||
| Days payables outstanding | 16,670.7 | 1,695.6 | 9,450.1 | 10,152.9 | 22,216.3 | 225,570.0 |
| Payables turnover | 0.02 | 0.22 | 0.04 | 0.04 | 0.02 | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $1.2M | $1.3M | $2.5M | $1.9M | $913,000 | $618,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from JBIO's annual financial statements (latest annual report filed March 6, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
JBIO valuation and financial ratios
Jade Biosciences earned a return on equity of −62.3% in fiscal 2025. It ended the year with $0.7 million of debt and $336.2 million in cash and short-term investments, a net cash position of $335.4 million.
See the JBIO income statement, the JBIO chart for price history, or the JBIO stock overview for the latest quote and news.
JBIO key metrics FAQ
What is Jade Biosciences's return on equity?
Jade Biosciences's return on equity (ROE) was −62.3% in fiscal 2025: net income of -$127.4 million on average shareholders' equity of $204.5 million.
How much debt does Jade Biosciences have?
Jade Biosciences had total debt of $0.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Jade Biosciences's free cash flow yield?
Jade Biosciences generated -$94.9 million of free cash flow in fiscal 2025, a free cash flow yield of −19.6% on its market value at year-end ($483.9 million).
What is Jade Biosciences's current ratio?
Jade Biosciences's current ratio was 20.33 at the end of fiscal 2025: current assets were 20.33 times current liabilities.